Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

P2Y(2) purinergic receptors are highly expressed in cardiac and diaphragm muscles of mdx mice, and their expression is decreased by suramin

Full text
Author(s):
Moreira, Drielen De Oliveira ; Neto, Humberto Santo ; Marques, Maria Julia
Total Authors: 3
Document type: Journal article
Source: MUSCLE & NERVE; v. 55, n. 1, p. 116-121, JAN 2017.
Web of Science Citations: 3
Abstract

Introduction: In Duchenne muscular dystrophy (DMD) and in the mdx mouse model of DMD, the lack of dystrophin leads to increased calcium influx and muscle necrosis. Patients suffer progressive muscle loss, and cardiomyopathy is an important determinant of morbidity. P2 purinergic receptors participate in the increased calcium levels in dystrophic skeletal muscles. Methods: In this study, we evaluated whether P2 receptors are involved in cardiomyopathy in mdx mice at later stages of the disease. Results: Western blotting revealed that P2Y(2) receptor levels were upregulated (54%) in dystrophic heart compared with a normal heart. Suramin reduced the levels of P2Y(2) to almost normal values. Suramin also decreased heart necrosis (reduced CK-MB) and the expression of the stretch-activated calcium channel TRPC1. Conclusions: This study suggests that P2Y(2) may participate in cardiomyopathy in mdx mice. P2-selective drugs with specific actions in the dystrophic heart may ameliorate cardiomyopathy in dystrophinopathies. Muscle Nerve55: 116-121, 2017 (AU)

FAPESP's process: 12/03498-7 - Mechanistic insights on the effects of suramin, on the cardiomyopathy of the mdx mice.
Grantee:Drielen de Oliveira Moreira
Support type: Scholarships in Brazil - Doctorate
FAPESP's process: 14/04782-6 - Pre-clinical studies in the mdx mouse: metabolomics, biomarkers and omega-3 therapy
Grantee:Maria Julia Marques
Support type: Regular Research Grants